Brief: Oragenics Prepares Drug For Phase II Clinical Trials To Treat Concussion
05/03/2024 12:49
March 5 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS, INC. PREPARES DRUG FOR PHASE II CLINICAL TRIALS
TO
TREAT CONCUSSION
* ORAGENICS INC - A 40-PATIENT PHASE I HUMAN STUDY SHOWED
ONP-002
TO BE SAFE AND WELL-TOLERATED.
* ORAGENICS INC - CURRENTLY MANUFACTURING ACTIVE
PHARMACEUTICAL
INGREDIENT (API) THAT WILL THEN BE FORMULATED AND SPRAY DRIED AS
A NANOPARTICLE POWDER
* ORAGENICS INC: DRUG CANDIDATE IS EXPECTED TO BE COMBINED
WITH
ITS NOVEL INTRANASAL DEVICE, FOR TREATMENT OF MILD TRAUMATIC
BRAIN INJURY
Source text for Eikon: ID:nBwnlWkXa
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing